Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Tributary Capital Management LLC

Key Points

• Tributary Capital Management LLC reduced its holdings in Supernus Pharmaceuticals by 7.0%, now owning around 0.55% of the company, valued at approximately $9.7 million.
• Insider transactions revealed significant sales, including SVP Frank Mottola selling 5,000 shares and CFO Timothy C. Dec selling 11,780 shares, reflecting a 24.40% and 90.43% decrease in their holdings, respectively.
• Various analysts have provided mixed ratings on the stock, with Cantor Fitzgerald raising their price target to $63.00 and Zacks Research upgrading it to a strong-buy rating, while Wall Street Zen downgraded it to a hold.

Tributary Capital Management LLC lowered its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 7.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 308,587 shares of the specialty pharmaceutical company's stock after selling 23,392 shares during the period. Tributary Capital Management LLC owned about 0.55% of Supernus Pharmaceuticals worth $9,727,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Supernus Pharmaceuticals in the first quarter worth about $41,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Supernus Pharmaceuticals in the first quarter worth about $46,000. GAMMA Investing LLC boosted its holdings in shares of Supernus Pharmaceuticals by 116.7% during the second quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company's stock worth $90,000 after purchasing an additional 1,541 shares during the period. CWM LLC boosted its holdings in shares of Supernus Pharmaceuticals by 92.4% during the second quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company's stock worth $97,000 after purchasing an additional 1,479 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in shares of Supernus Pharmaceuticals during the first quarter worth approximately $103,000.

Insider Transactions at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 5,000 shares of the business's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $45.87, for a total transaction of $229,350.00. Following the transaction, the senior vice president owned 15,496 shares of the company's stock, valued at approximately $710,801.52. The trade was a 24.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the transaction, the chief financial officer directly owned 1,246 shares in the company, valued at $55,434.54. This trade represents a 90.43% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 362,741 shares of company stock worth $16,390,592. 8.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

SUPN has been the subject of several research reports. Wall Street Zen cut shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, October 3rd. Cantor Fitzgerald raised their price target on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a report on Tuesday, September 30th. Weiss Ratings restated a "hold (c)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday, October 8th. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $40.00 to $65.00 in a research note on Thursday, October 9th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $64.00.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $50.67 on Thursday. The firm has a fifty day simple moving average of $46.47 and a 200-day simple moving average of $37.63. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $52.15. The stock has a market capitalization of $2.84 billion, a price-to-earnings ratio of 44.06 and a beta of 0.78.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.